Close
Enter your
text here

CFTR

New Health Challenges in the Post-CFTR Modulator Era
 New Health Challenges in the Post-CFTR Modulator Era 1024 576 Lauren Dembeck
By: Lauren Dembeck

The remarkable progress in CF care has also revealed new challenges. As individuals with CF live longer, clinicians are seeing higher frequencies of complications and other down- stream health concerns that rarely emerged in the past and are now focused on aging-related diseases and maintaining their overall health. Karen McCoy, MD, pediatric pulmonologist and renowned…

Modulator Therapy Improves Chronic Sinus Disease in Individuals with Cystic Fibrosis
 Modulator Therapy Improves Chronic Sinus Disease in Individuals with Cystic Fibrosis 1024 683 Mary Bates, PhD
By: Mary Bates, PhD

Following 1 year of therapy, patients showed improved sinus CT metrics and clinical outcomes. Over the last decade, the development of cystic fibrosis transmembrane conductance regulator (CFTR) modulator drugs has revolutionized the treatment of cystic fibrosis (CF). The most widely used modulator is the triple combination elexacaftor-tezacaftor-ivacaftor (ETI), which is approved for people with CF…